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1 
2 
3 Abstract 
4 
5 
6 Objective: To clarify the details of homogenously enhancing lesions on 
7 
8 
9 
10 contrast–enhanced ultrasonography (CEUS) and also to elucidate whether 
11 
12 
13 their differential diagnosis is possible. 
14 
15 
16 Methods: 73 homogenously enhancing lesions on CEUS were retrospectively 
17 
18 
19 selected. Two radiologists first assessed conventional US findings alone in 
20 
21 
22 consensus to differentiate malignant vs benign lesions. Then, qualitative 
23 
24 
25 and quantitative CEUS findings were analyzed to determine the useful 
27 
28 
29 findings for differential diagnosis. Determined CEUS findings were applied 
30 
31 
32 to the indeterminate lesions based on conventional US findings to see 
33 
34 
35 whether CEUS may improve the diagnostic performance. 
36 
37 38 Results: There were 42 cancers (58%) out of 73. Sensitivity and specificity 
39 
40 41 using conventional US findings alone were 91% and 55%, respectively. Among 
42 
43 
44 the CEUS findings tested, multivariate analysis revealed only the type 3 
46 
47 
48 enhancement  pattern,  which  indicates  larger  enhancing  area  than  the 
49 
50 
51 precontrast hypoechoic lesion, was related to malignity (p<0.05). By adding 
52 
53 
54 this information, however, no improvement was achieved in the diagnostic 
55 
56 
57 performance as determined by conventional US findings. 
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3 Conclusions: Approximately half of the homogeneously enhancing lesions on 4 
5 6 CEUS are malignant, and differentiation of malignant from benign lesions 7 
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10 may be possible, at least to some extent, by meticulous assessment of the 
11 
12 
13 conventional US findings, rather than CEUS findings. 
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1 
2 
3 INTRODUCTION 
4 
5 
6 With the advent of contrast agent for ultrasonography, several researchers 
7 
8 
9 
10 have applied this technique, namely contrast enhanced ultrasonography 
11 
12 
13 (CEUS), to breast imaging, and not a few promising data have been published 
14 
15 
16 in terms of malignancy vs benignity differentiation [1-4]. Generally, it has 
17 
18 
19 been  reported  that  irregularly  or  peripherally  enhancing  lesions  are 
20 
21 
22 malignant,  whereas  homogeneously  enhancing  ones  are  benign  [1-3]. 
23 
24 
25 However, we encounter considerable number of “exceptional” cases in daily 
27 
28 
29 practice, which are against the above mentioned rules, particularly for the 
30 
31 
32 latter  [4-6]. To our knowledge, little has been investigated specifically 
33 
34 
35 focused on the differential diagnosis of homogeneously enhancing lesions on 
36 
37 
38 CEUS. 
39 
40 41 This  study  was  conducted,  therefore,  to  clarify  the  clinico-pathological 
42 
43 
44 details of “homogeneously  enhancing lesion” on  CEUS,  and to elucidate 
46 
47 
48 whether  differentiation  between  malignant  and  benign  lesions  in  this 
49 
50 
51 particular cohort is possible. 
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1 
2 
3 MATERIALS AND METHODS 
4 
5 
6 Between October 2012 and August 2015, 134 patients with 161 suspected 
7 
8 
9 
10 breast lesions underwent CEUS in our institute. Among these, the lesions 
11 
12 
13 which showed homogeneous enhancement at their peaks, and also for whom 
14 
15 
16 final pathological diagnoses were obtained, were retrospectively recruited. In 
17 
18 
19 our institute, CEUS is routinely performed as a presurgical procedure, or for 
20 
21 
22 patients  whose  diagnosis  is  indeterminate  or  questionable  based  on 
23 
24 
25 conventional  radiological  workup.  Our  institutional  review  board waved 
27 
28 
29 obtaining informed consent because of its retrospective nature. 
30 
31 
32 CEUS  was performed  with a  clinical ultrasound  unit  (LOGIQ  E9, GE 
33 
34 
35 HealthCare,  Milwalkee,  WI). Conventional  and  contrast-enhanced  US 
36 
37 
38 images were obtained with a ML 6-15MHz and a SL 9MHz linear probes, 
39 
40 41 respectively. Mechanical index was set at 0.2-0.21. After confirming that 
42 
43 
44 the target lesions were well visualized at the center of field-of-views, bolus 
46 
47 
48 injection of contrast medium (Sonazoid, Daiichi Sankyo, Tokyo, Japan) of 
49 
50 
51 0.015 mL/kg was performed from the antecubital vein, followed by 10mL 
52 
53 
54 saline flush. The target lesions were then continuously observed for 90s using 
55 
56 
57 real-time grayscale harmonic imaging, the whole process of which was video- 
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1 
2 
3 recorded. 
4 
5 
6 All sonographic images and videos were reviewed by two experienced 
7 
8 
9 
10 radiologists  (RF  and  MS)  who  were  experienced  in  breast  sonographic 
11 
12 
13 imaging and blinded to the pathological results. First, the conventional US 
14 
15 
16 images alone were evaluated, and the confidence level of diagnosing malignity 
17 
18 
19 was determined using 5-poin scale in consensus, with scores 1, 2, 3, 4, and 5 
20 
21 
22 indicating definitely benign, possibly benign, indeterminate, possibly 
23 
24 
25 malignant, and definitely malignant, respectively, according to the previously 
27 
28 
29 reported criteria, namely, Breast Imaging Reporting and Data System (BI- 
30 
31 
32 RADS) 2013 [7] for mass lesions and those defined by Ko et al. [8] for non- 
33 
34 
35 mass-like lesions. As for mass lesions, the final score of a certain patient was 
36 
37 
38 determined based on the total balance of the assessment for each finding of 
39 
40 41 BI-RADS 2013 (Table 1); more specifically, the all findings listed in Table 1 
42 
43 
44 were checked for each lesion, and if findings favoring malignity or benignity 
46 
47 
48 were dominant, scores 4-5 or 1-2 were given, respectively; if these were 
49 
50 
51 similar in number, score 3 was given. As for non-mass lesions, types Ib and 
52 
53 
54 IIb, were considered malignant, whereas the rest were benign or 
55 
56 
57 indeterminate  (Table  1).  Scores  4  and  5  were  regarded  as  suggesting 
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1 
2 
3 malignancy, respectively, and sensitivity and specificity were calculated. 
4 
5 
6 Then, the enhancement patterns of the lesions on CEUS were reviewed and 
7 
8 
9 
10 divided  into  the  following  three  groups;  type1,  in  which  the  degree  of 
11 
12 
13 enhancement of the lesions was almost equal to the surrounding breast tissue, 
14 
15 
16 type  2,  where  the  degree  of  enhancement  was  greater  than  that  of 
17 
18 
19 surrounding tissue with the area of enhancement being approximately the 
20 
21 
22 same as the precontrast hypoechoic lesion in size, and type 3, in which the 
23 
24 
25 degree of enhancement was greater than that of surrounding tissue, and the 
27 
28 
29 area of enhancement was larger than the hypoechoic lesion on the precontrast 
30 
31 
32 images. On the dynamic phase of contrast enhancement, one radiologist 
33 
34 
35 (RF) manually placed region-of-interest to cover the whole lesion as visualized 
36 
37 
38 on the initial images before contrast arrival, and time-intensity-curve (TIC) 
39 
40 41 was created, and following indices were semi-automatically calculated: Axk 
42 
43 
44 value was defined as the slope of the tangent at the beginning of TIC 
46 
47 
48 ; time to peak (TTP) was defined as the time period in sec between the 
49 
50 
51 beginning point to the peak of TIC: ascending slope (AS) was defined as the 
52 
53 
54 slope between the beginning point to the peak of TIC. 
55 
56 
57 The correlation between these CEUS parameters (enhancement patterns, 
58 
59 
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1 
2 
3 Axk, TTP, and AS) and malignity vs benignity were assessed and significant 
4 
5 
6 factors for differentiation were sought. Significant factors, if present, were 
7 
8 
9 
10 applied to the above mentioned score 3 groups, namely indeterminate lesions 
11 
12 
13 when assessed solely with conventional US image findings, and sensitivity 
14 
15 
16 and  specificity  were  again  calculated  to  check  whether  adding  CEUS 
17 
18 
19 information might improve the diagnostic capability. 
20 
21 
22 For  statistical  analyses,  Wilcoxon  Kruskal-Wallis  test,  Fisher’s  exact 
23 
24 
25 probability test, and χ2 test, were used for univariate analyses, and logistic 
27 
28 
29 regression test was used for multivariate analysis. P values of less than 0.05 
30 
31 
32 were considered significant. The statistical software used was JMP version 
33 
34 
35 11 (SAS corporation, Cary, USA). 
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1 
2 
3 RESULTS 
4 
5 
6 There were 73 patients with 73 lesions with age ranging from 34 to 80 years 
7 
8 
9 
10 old (mean 53.2), including 10 fibroadenoma/phyllodes tumors, 12 intraductal 
11 
12 
13 papillomas, 19 ductal adenocarcinoma in situ (DCIS), 23 invasive ductal 
14 
15 
16 adenocarcinomas (IDC), and 9 other non-specific benign lesions (NSBL). 
17 
18 
19 Namely, 58% (42/73) of homogeneously enhancing lesions were malignant in 
20 
21 
22 our patient population. All NSBL showed fibrocystic change or adenosis with 
23 
24 
25 or without slight inflammatory cell infiltration. The lesions size ranged from 
27 
28 
29 4 to 85 mm in their maximum dimension, with malignant lesions (19.5
30 
31 
32 15.1mm)  being  larger  than  benign  ones  (10.5 6.3mm).  Among  these, 
33 
34 
35 histological diagnoses were made by surgical resection, percutaneous needle 
36 
37 
38 biopsy, and cytology for 50, 19, and 4 lesions, respectively. 
39 
40 
41 
42 
43 
44 Diagnosis solely based on conventional US findings 
46 
47 
48 As for mass lesions, two, one, 12, 27, and 7 lesions were given score 1, 2, 3, 
49 
50 
51 4, and 5, respectively; as for non-mass lesions, there were 0, 0, 6, 10, and 8. 
52 
53 
54 In total, two, one, 18, 37, and 15 lesions were graded as score 1, 2, 3, 4, and 5, 
55 
56 
57 respectively by the two reviewers. The three lesions given scores 1 or 2 were 
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1 
2 
3 all benign, and 15 lesions given scores 5 were all malignant. Those scored 
4 
5 
6 as 3 (indeterminate lesions) included 14 benign and 4 malignant lesions. 
7 
8 
9 
10 Those scored as 4 (probably malignant) included 14 benign and 23 malignant 
11 
12 
13 lesions. Thus, when scores 4 and 5 were considered to suggest malignity, 
14 
15 
16 sensitivity, specificity, and accuracy were 90.5% (38/42), 54.8% (17/31), and 
17 
18 
19 75.3% (55/73), respectively. 
20 
21 
22 
23 
24 
25 CEUS findings 
27 
28 
29 The details of the CEUS findings vs histological classification are shown 
30 
31 
32 in Table 2. When histology was simply divided into benign vs malignant, 
33 
34 
35 enhancement  pattern  was  the  only  significant  factor,  suggesting  type  3 
36 
37 
38 enhancement pattern was significantly related to malignancy. When each 
39 
40 41 disease  entity  was  separately  considered,  univariate  analysis  suggested 
42 
43 
44 enhancement  pattern  and  Axk  were  significant  factors,  with  type  3 
46 
47 
48 enhancement pattern being associated with IDC, and Axk of NSBL being 
49 
50 
51 smaller  than  those  of  IP  (Table  1).  No  other  indices  were  significantly 
52 
53 
54 different among the disease entities. Multivariate analysis revealed that only 
55 
56 
57 enhancement pattern was independently significant with the likelihood ratio 
58 
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65 
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1 
2 
3 χ2 (Chi-square) values of 13.1. 
4 
5 
6 
7 
8 
9 
10 Diagnosis using both conventional US and CEUS findings 
11 
12 
13 The significant parameter in CEUS finding, namely enhancement pattern, 
14 
15 
16 was attempted to be incorporated into the diagnosis using conventional US 
17 
18 
19 findings, however, all 8 lesions showing type 3 enhancement pattern had 
20 
21 
22 already been diagnosed as malignant by conventional US findings (two and 
23 
24 
25 six lesions were scored as 5 and 4, respectively). Thus, incorporating CEUS 
27 
28 
29 finding into conventional US findings did not improve diagnostic performance 
30 
31 
32 in terms of malignant vs benign differentiation. 
33 
34 
35 Representative cases are shown in Fig.s 1-3. 
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1 
2 
3 DISCUSSION 
4 
5 
6 Our results suggested homogeneously enhancing lesions are not necessarily 
7 
8 
9 
10 benign, but considerable number of malignancy (approximately 60% in our 
11 
12 
13 cohort) can be included in this group of lesions. Among these, approximately 
14 
15 
16 75%  of  lesions  can  be  correctly  diagnosed  as  benign  or  malignant  by 
17 
18 
19 conventional US findings alone, but one quarter of them (18/73) remain 
20 
21 
22 indeterminate. 
23 
24 
25 As for CEUS findings, our factor analysis revealed enhancement pattern and 
27 
28 
29 Axk values were significantly related to the final diagnoses of the lesions. 
30 
31 
32 Actually, all 8 lesions showing type 3 enhancement pattern (the degree of 
33 
34 
35 enhancement was greater than that of surrounding tissue, and the area of 
36 
37 
38 enhancement  was  larger  than  the  hypoechoic  lesion  on  the  precontrast 
39 
40 41 images) were IDC. Histopathological correlation revealed two of these lesions 
42 
43 
44 showed strong lymphocytic infiltration around the marginal areas of the 
46 
47 
48 lesions  (Fig.3).  Similar  observation,  namely  peritumoral  enhancement 
49 
50 
51 around IDC, has already been reported, which have been attributed to DCIS 
52 
53 
54 component around IDC, adenosis with lobular hyperplasia or inflammatory 
55 
56 
57 cell  infiltration  around  IDC  [5,  9-10].  A  “crab-craw  like  microvascular 
58 
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1 
2 
3 architecture” or increased microvessel density or vascular endothelial growth 
4 
5 
6 factor expression may be related to this findings [5, 10-12]. 
7 
8 
9 
10 In contrast to the previous report [1, 6, 9], quantitative indices derived from 
11 
12 
13 TIC did not serve to the differential diagnosis, except for Axk values, which 
14 
15 
16 were useful only in differentiating NSBL from IP. NSBL and IP tended to 
17 
18 
19 show lower and higher Axk values, respectively, among the disease entities 
20 
21 
22 included in this study. NSBL in our population consisted of fibrocystic 
23 
24 
25 change or adenosis with or without slight inflammatory cell infiltration, 
27 
28 
29 possibly  representing  mastopathy  or  chronic  mastitis. We  presume 
30 
31 
32 angiogenic features may be similar regardless of it benignity or malignity in 
33 
34 
35 this particular cohort. In addition, multivariate analysis revealed that only 
36 
37 
38 enhancement pattern, not Axk, was the independently significant factor in 
39 
40 41 the differential diagnosis. 
42 
43 
44 Adding the significant factor derived from CEUS, namely enhancement 
46 
47 
48 pattern, however, did not improve diagnostic performance solely based on 
49 
50 
51 conventional US findings. All lesions showing type 3 enhancement pattern 
52 
53 
54 had readily been diagnosed as malignant, using conventional US findings 
55 
56 
57 (Table 1). Thus, CEUS findings, either qualitative or quantitative, added little 
58 
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1 
2 
3 to the differential diagnosis of homogeneously enhancing lesions on CEUS. 
4 
5 
6 We  therefore  recommend  looking  back  the  conventional  US  findings 
7 
8 
9 
10 meticulously when dealing with the lesions in this particular cohort. 
11 
12 
13 There are several limitations in this study, in addition to the retrospective 
14 
15 
16 nature. First, although the total number of subjects were over 70, both benign 
17 
18 
19 and  malignant lesions  included  various  entities  of  limited  number,  and 
20 
21 
22 therefore our result may not be applicable to different cohort of different 
23 
24 
25 disease configuration. Ideally, our results should have been tested in another 
27 
28 
29 cohort consisting of homogeneously enhancing lesions. Second, because the 
30 
31 
32 enhancement pattern of the lesions was assessed as compared to that of the 
33 
34 
35 background breast tissue, the results would be affected by the condition of the 
36 
37 
38 background tissue, for example menstrual cycle or age-related fatty change, 
39 
40 41 in addition to that of the lesions themselves. Third, placement of ROI to 
42 
43 
44 create TIC and subsequent quantitative indices measurement was performed 
46 
47 
48 by one radiologist, which may have caused some bias in the results. Fourth, 
49 
50 
51 qualitative assessment was made by two radiologists in consensus, not by 
52 
53 
54 independent interpretation, which also may have resulted in some bias. 
55 
56 
57 Further prospective study with larger population and meticulous design 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
 
1 
2 
3 would be needed to solve these problems. 
4 
5 
6 In conclusion, radiologists should be aware that almost half of 
7 
8 
9 
10 homogeneously enhancing lesions on CEUS are malignant, and 
11 
12 
13 differentiation of malignant from benign lesions may be possible, at least to 
14 
15 
16 some extent, by meticulously referring to the conventional US findings, not 
17 
18 
19 to CEUS findings. 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
26 
13 
 
 
1 
2 
3 References 
4 
5 
6 1.  Zhao H, Xu R, Ouyang Q,ChenL, Dong B, Huihua Y, Contrast-enhanced ultrasound 
7 
8 
9 
10 is helpful in the differentiation of malignant and benign breast lesions. Euro J Radio. 
11 
12 
13 2010; 73: 288-293 
14 
15 
16 2.  Du J, Wang L, Wan CF, Hua J, Fang H, Chen J, Li FH. Differentiating benign from 
17 
18 
19 malignant solid breast lesions: Combined utility of conventional ultrasound and 
20 
21 
22 contrast enhanced ultrasound in comparison with magnetic resonance imaging. Eur J 
23 
24 
25 Radiol 2012; 33: 3890–3899. 
27 
28 
29 
30 3.  Miyamoto Y, Ito T, Takada E, Omoto K, Hirai T, Moriyasu F. Efficacy of Sonazoid 
31 
32 
33 (Perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast 
34 
35 
36 lesions: Phase 3 multicenter clinical trial. AJR 2014; 202: W400-407 
37 
38 39 4.  H.Liu, YX Jiang, JB Liu, et al. Evaluation of breast lesions with contrast-enhanced 
40 
41 42 ultrasound using the microvascular imaging technique: Initial observations. The 
43 
44 
45 
46 Breast 2008; 17: 532-539 
47 
48 
49 5.  H.Liu, YX.Jiang, JB Liu, et al. Contrast-enhanced breast ultrasonography Imaging 
50 
51 
52 features with histopathologic correlation. J Ultrasound Med. 2009; 28: 911-920 
53 
54 
55 6.  Wan CF, Du J, Fang H, et al. Evaluation of breast lesions by contrast enhanced 
56 
57 58 ultrasound: Qualitative and quantitative analysis. Euro J Radio 2012:81:e444-e450 
59 
60 
61 
62 
63 
64 
65 
26 
45 
14 
 
 
1 
2 
3 7.  American College of Radiology. BI-RADS	 – Ultrasound 2013. 
4 
5 6 http://www.acr.org/Quality-Safety/Resources/BIRADS/Ultrasound 
7 
8 
9 
10 8.  Ko KH, Hsu HH, Yu JC, et al. Non-mass-like breast lesions at ultrasonography: 
11 
12 
13 feature analysis and BI-RADS assessment. EJR 2015;84:77-85 
14 
15 
16 9.  Jiang YX, Liu H, Liu JB, et al. Breast tumor size assessment: Comparison of 
17 
18 
19 conventional ultrasound and contrast-enhanced ultrasound. Ultrasound in Med. & 
20 
21 
22 Biol. 2007; 33: 1873-1881. 
23 
24 
25 10. Du J, Li FH, Fang H, et al. Microvascular Architecture of Breast Lesions; 
27 
28 
29 Evaluation With Contrast-Enhanced Ultrasonographic Micro Flow Imaging. J 
30 
31 
32 Ultrasound Med. 2008; 27: 833-842 
33 
34 
35 11. YJ.Li, G Men, Y Wang, et al. Perfusion heterogeneity in breast tumors for assessment 
36 
37 
38 of angiogenesis. J Ultrasound Med. 2013; 32:1145-1155 
39 
40 
41 12. Liu H, Jiang YX, Dai Q, et al. Peripheral enhancement of breast cancers on contrast- 
42 
43 
44 
enhanced ultrasound: Correlation with microvessel density and vascular endothelial 
46 
47 
48 growth factor expression. Ultrasound in Med. & Biol., 2014;40: 293–299 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
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18 
19 15 
20 
21 
22 
23 Table 1 Criteria for malignity and benignity of the lesions based on conventional sonographic findings before contrast 
24 25 enhancement 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 * Original reference #7 includes other factors including skin appearances, Doppler or elastography information. 
56 However, in our patients, none showed skin thickening, skin retraction, or edema: Doppler sonography and elastography 57 
58 were obtained in limited number of cases. These findings were therefore omitted in the table. 
59 ** Type I ductal non-mass-like (NML) pattern: parallel orientation of multiple duct-like structures without calcifications 
60 
61 
62 
63 
64 
65 
	 	 benign indeterminate malignant 
Mass lesion [7]* 
	 shape Oval Round Irregular 
	 orientation Parallel to the 
skin 
	 Not parallel to the skin 
	 margin Circumscribed Microlobulated angular, indistinct, spiculated 
	 internal echo Aechoic,
hyperechoic 
Isoechoic, hypoechoic Complex, 
	 posterior acoustic
features 
	 Enhancement,
None 
shadowing, combined 
	 calcification 	 	 In mass, intraductal 
	 architectural
distortion 
	 	 yes 
	 Duct change 	 	 yes 
Non-mass lesion [8]** 
	 types 	 type Ia, type IIa, type III, type IV type Ib, type IIb 
	
15 
16 
17 
18 
19 16 
20 
21 
22 
23 (type Ia) or with associated calcifications (type Ib). Type II nonductal NML pattern: a geographic or mottled area that 
24 does not give a discrete mass, and may present without calcifications (type IIa) or with associated calcifications (type 
25 IIb). Type III NML pattern: associated with architectural distortion, Type IV NML pattern: associated with posterior 26 
27 acoustic shadowing [8]. 
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35 
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40 
41 
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44 
45 
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15 
16 
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23 Table 2 Correlation between contrast-enhanced US findings and histology 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 CEUS: contrast-enhanced ultrasonography, Enh.pattern: enhancement pattern, Axk: the slope of the tangent at the 
46 
47 
48 beginning of time-intensity-curve, TTP: time to peak, AS; ascending slope. 
49 
50 
51 FA: fibroadenoma, Phyl: phyllodes tumor, IP: intraductal papilloma, NSBL: non-specific benign lesion, IDC: invasice 
52 
53 
54 ductal carcinoma, DCIS: ductal carcinoma in situ, Uni: univariate analysis, Mul: multivaraiate analysis 
55 
56 indicates NSBL vs IP 
58 
59 
60 
61 
62 
63 
64 
65 
CEUS 
findings 
benign malignant P 
values 
Disease entities P values 
benign malignant 
FA/Phyl IP NSBL IDC DCIS Uni Mul 
Ehn.pattern 
Type 1/2/3 
14/17/0 23/11/8 0.004 3/7/0 4/8/0 7/2/0 11/4/8 12/7/0 0.01 0.0005 
Axk 6.5 ± 3.2 7.1 ± 3.5 NS 6.8 ± 2.5 8.2 ± 3.3 4.1 ± 2.0 7.4 ± 4.2 6.8 ± 2.6 0.044* NS 
TTP 9.6 ± 3.0 9.7 ± 4.8 NS 9.3 ± 2.2 8.9 ± 1.4 10.1 ± 5.8 10.8 ± 4.6 8.9 ± 4.5 NS 	
AS 2.2 ± 0.8 2.2 ± 1.0 NS 2.3 ± 0.7 2.4 ± 0.5 1.9 ± 1.1 2.2 ± 1.1 2.2 ± 0.9 NS 	
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1 
2 
3 Figure legends 
4 
5 
6 Fig.1 Pathologically proven fibroadenoma in a 65 year-old woman. 
7 
8 
9 
10 1a Conventional sonography revealed an oval shaped, well circumscribed 
11 
12 
13 mass of 10 mm in its greatest dimension, with an internal echogenicity 
14 
15 
16 similar to that of the adjacent adipose tissue, associated with slight posterior 
17 
18 
19 acoustic enhancement (arrows). 
20 
21 
22 1b Contrast-enhanced sonography showed homogeneous enhancement of 
23 
24 
25 the lesion, corresponding to type 2 enhancement pattern (arrows). Axk value 
27 
28 
29 was semi-automatically calculated to be 3.82 (time-intensity curve not shown). 
30 
31 
32 1c Microscopic appearance of the lesion (hematoxylin and eosin staining, 
33 
34 
35 original magnification x100). Arrow indicate the boundary of the lesion. 
36 
37 
38 
39 
40 41 Fig.2 Ductal carcinoma in situ in a 41 year-old woman. 
42 
43 
44 2a Conventional sonography reveals a well-demarkated hypoechoic lesion 
46 
47 
48 without mass formation, measuring 30 mm in its greatest dimension (arrows). 
49 
50 
51 2b Contrast-enhanced sonography showed homogeneous enhancement of 
52 
53 
54 the whole lesion, which is indistinguishable from the background tissue, in 
55 
56 
57 keeping with  type  1 enhancement pattern. Axk value  was semi- 
58 
59 
60 
61 
62 
63 
64 
65 
26 
45 
19 
 
 
1 
2 
3 automatically calculated to be 8.22 (time-intensity curve not shown). 
4 
5 
6 2c Microscopic appearance of the lesion (hematoxylin and eosin staining, 
7 
8 
9 
10 original magnification x200). Arrow indicate the calcification within the 
11 
12 
13 lesion.. 
14 
15 
16 
17 
18 
19 Fig.3 Invasive ductal carcinoma in a 49 year-old woman. 
20 
21 
22 3a Conventional sonography reveals an irregularly shaped hypoechoic 
23 
24 
25 mass of 24 mm in its greatest dimension, showing spicualted margin and 
27 
28 
29 slight posterior shadowing (arrows). 
30 
31 
32 3b Contrast-enhanced sonography showed homogeneous enhancement, the 
33 
34 
35 size of which was larger than the hypoechoic area as observed on precontrast 
36 
37 
38 image, in keeping with type 3 enhancement pattern. Axk value was 3.08 
39 
40 41 (time-intensity curve not shown) 
42 
43 
44 3c Pathological  specimen  reveals  prominent  lymphocytic  infiltration 
46 
47 
48 (arrows) around the margin of the lesion (C), which may explain the extensive 
49 
50 
51 peritumoral enhancement (hematoxylin and eosin stain, original 
52 
53 
54 magnification x 200). 
55 
56 
57 
58 
59 
60 
61 
62 
63 
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65 
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